These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 21395580

  • 1. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range.
    Wang G, Krishnamurthy K, Tangpisuthipongsa D.
    J Neurochem; 2011 May; 117(4):703-11. PubMed ID: 21395580
    [Abstract] [Full Text] [Related]

  • 2. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 3. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

  • 4. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 5. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 6. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 7. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation.
    Yun BG, Matts RL.
    Cell Signal; 2005 Dec 15; 17(12):1477-85. PubMed ID: 15935620
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH, Tseng SC, Huang YC, Chen HJ, Lin YW.
    Biochem Pharmacol; 2012 Jul 01; 84(1):126-36. PubMed ID: 22480737
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
    Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, Shao Y, Zagzag D.
    Anticancer Drugs; 2007 Sep 01; 18(8):875-82. PubMed ID: 17667592
    [Abstract] [Full Text] [Related]

  • 11. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
    Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL.
    J Neurochem; 2006 Dec 01; 99(5):1351-62. PubMed ID: 17064348
    [Abstract] [Full Text] [Related]

  • 12. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
    Lukasiewicz E, Miekus K, Kijowski J, Gozdzik J, Wilusz M, Bobis-Wozowicz S, Wiecha O, Majka M.
    J Physiol Pharmacol; 2009 Sep 01; 60(3):161-6. PubMed ID: 19826195
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    Proteomics; 2007 Aug 01; 7(15):2603-16. PubMed ID: 17610208
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 16. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
    Wu WC, Wu MH, Chang YC, Hsieh MC, Wu HJ, Cheng KC, Lai YH, Kao YH.
    Exp Eye Res; 2010 Aug 01; 91(2):211-9. PubMed ID: 20493187
    [Abstract] [Full Text] [Related]

  • 17. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.
    J Surg Res; 2012 Jul 01; 176(1):147-53. PubMed ID: 22099584
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 20. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
    Yu WJ, Rao Q, Wang M, Tian Z, Xu ZF, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 01; 28(10):677-80. PubMed ID: 18399173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.